Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

: Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G.B., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C., Lane R.M.

Publisher: Nature Research

: 2024

: Nature Medicine

: 304

: 30

: 1078-8956

: 1546-170X

DOI: https://doi.org/10.1038/s41591-023-02639-3

: https://www.nature.com/articles/s41591-023-02639-3

: https://research.utu.fi/converis/portal/detail/Publication/181983815

s41591-023-02639-3.pdf